Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA IS BEGINNING TO SHOW SIGNS OF "SWITCH LAG"

This article was originally published in The Tan Sheet

Executive Summary

FDA IS BEGINNING TO SHOW SIGNS OF "SWITCH LAG," Nonprescription Drug Manufacturers Association President James Cope suggested during his May 15 report at the association's annual meeting in White Sulfur Springs, W. Va. Cope pointed out that the U.K. adheres to a "one-year target to process switch applications." He noted that "while the transfer of safe and effective prescription products to OTC status is a worldwide trend, the U.S. lags behind other countries in some categories." Throughout the 1970s, companies in the U.S. prescription drug business alleged that a "drug lag" existed between approvals of new prescription products in the U.S. compared to Europe.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel